See available savings for eligible patients with and without prescription insurance*
Commercially insured patients pay no more than $35* per 30-day supply.
Your uninsured or insured patients who prefer to pay cash outside of their prescription drug benefit will pay $35* per 30-day supply.
Patients pay $35* per 30-day monthly supply of any one or combination of Sanofi Insulins. All insulin prescriptions must be filled at the same time from the pharmacy.
See examples below of 3 different monthly supply needs, but patient paying one set price:
6 x 10mL vials $35
2 pack of pens $35
2 x 10mL vials + 2 pack of pens $35
Important Safety Information
Contraindications
Apidra is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients.
Warnings and Precautions
Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles.
Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Dosing should be individualized based on patient characteristics and lifestyle.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.
Hypoglycemia is the most common adverse reaction associated with insulins, including Apidra, and maybe life-threatening.
To avoid medication errors between APIDRA and other insulins, instruct patients to always check the insulin label before each injection.
All insulin products, including Apidra, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including APIDRA. If hypersensitivity reactions occur, discontinue APIDRA, treat per standard of care and monitor until symptoms and signs resolve.
Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs.
Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
Adverse Reactions
Adverse reactions commonly associated with Apidra include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, and weight gain.
Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Important Safety Information for Apidra (insulin glulisine) injection SoloSTAR
Apidra SoloSTAR is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.
Important Safety Information for Apidra (insulin glulisine) injection Use in Pump
Inform patients to replace the infusion sets (reservoir, tubing, and catheter) and the Apidra in the reservoir at least every 48 hours and select a new infusion site. Pump failure or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Prompt identification and correction of the cause is necessary. Interim subcutaneous injections with APIDRA may be required. Patients using a pump must be trained to administer insulin by injection and have alternative insulin therapy available in case of pump system failure.
Indication
APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Click here for Full Prescribing Information for Apidra.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
*Eligibility & Offer Terms For Your Patients:
Sanofi Insulins Co-pay Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Sanofi Insulins Co-pay Savings Program at (866) 255-8661 (8:00 am-8:00 pm EST, Monday-Friday).
Insulins Valyou Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is only valid for those who are uninsured or those who are insured by a prescription plan but are not using such insurance and will be paying the full retail price for the medication. Void where prohibited by law. The Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. You may not submit claims for reimbursement to any third-party payor, including any government healthcare plan (e.g., Medicare, Medicaid, DOD, VA, TRICARE) or similar federal or state programs for Sanofi Insulin prescriptions when using this Program. You may not seek to have your out-of-pocket costs or the full retail price of the Sanofi Insulin count toward your deductible, true-out-of-pocket (TrOOP), maximum out-of-pocket (MOOP), or any other out-of-pocket caps associated with any insurance coverage. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Valyou Savings Program at (833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday).
